Malignant transformation of neurocutaneous melanosis (NCM) following immunosuppression

Lauren R. Schaff; Ashfaq Marghoob; Marc K. Rosenblum; Rina Meyer; Yasmin Khakoo

doi:10.1111/pde.13804

Malignant transformation of neurocutaneous melanosis (NCM) following immunosuppression

Lauren R. Schaff
, Ashfaq Marghoob
, Marc K. Rosenblum
, Rina Meyer
, Yasmin Khakoo

Pediatrics

Stony Brook University

Memorial Sloan-Kettering Cancer Center

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Neurocutaneous melanosis (NCM) is the condition of abnormal melanocyte deposition in the leptomeninges and brain parenchyma. Associated with congenital melanocytic nevi, NCM can result in neurologic deficits, hydrocephalus, and rarely, malignant transformation of cells. We present the case of a 16-year-old boy with NCM who developed malignant leptomeningeal melanoma following immunosuppression with a TNFα inhibitor. To our knowledge, this is the first reported case of a patient with known NCM undergoing malignant transformation after anti-TNF therapy for inflammatory bowel disease.

Original language	English
Pages (from-to)	497-500
Number of pages	4
Journal	Pediatric Dermatology
Volume	36
Issue number	4
DOIs	https://doi.org/10.1111/pde.13804
State	Published - Jul 1 2019

Keywords

TNF inhibitor
immunodeficiency
melanocytic nevi
neoplasms-malignant

Access to Document

10.1111/pde.13804

Cite this

@article{4fab09f28f1946c5bb333f2ab47a141e,

title = "Malignant transformation of neurocutaneous melanosis (NCM) following immunosuppression",

abstract = "Neurocutaneous melanosis (NCM) is the condition of abnormal melanocyte deposition in the leptomeninges and brain parenchyma. Associated with congenital melanocytic nevi, NCM can result in neurologic deficits, hydrocephalus, and rarely, malignant transformation of cells. We present the case of a 16-year-old boy with NCM who developed malignant leptomeningeal melanoma following immunosuppression with a TNFα inhibitor. To our knowledge, this is the first reported case of a patient with known NCM undergoing malignant transformation after anti-TNF therapy for inflammatory bowel disease.",

keywords = "TNF inhibitor, immunodeficiency, melanocytic nevi, neoplasms-malignant",

author = "Schaff, \{Lauren R.\} and Ashfaq Marghoob and Rosenblum, \{Marc K.\} and Rina Meyer and Yasmin Khakoo",

note = "Publisher Copyright: {\textcopyright} 2019 Wiley Periodicals, Inc.",

year = "2019",

month = jul,

day = "1",

doi = "10.1111/pde.13804",

language = "English",

volume = "36",

pages = "497--500",

journal = "Pediatric Dermatology",

issn = "0736-8046",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Malignant transformation of neurocutaneous melanosis (NCM) following immunosuppression

AU - Schaff, Lauren R.

AU - Marghoob, Ashfaq

AU - Rosenblum, Marc K.

AU - Meyer, Rina

AU - Khakoo, Yasmin

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Neurocutaneous melanosis (NCM) is the condition of abnormal melanocyte deposition in the leptomeninges and brain parenchyma. Associated with congenital melanocytic nevi, NCM can result in neurologic deficits, hydrocephalus, and rarely, malignant transformation of cells. We present the case of a 16-year-old boy with NCM who developed malignant leptomeningeal melanoma following immunosuppression with a TNFα inhibitor. To our knowledge, this is the first reported case of a patient with known NCM undergoing malignant transformation after anti-TNF therapy for inflammatory bowel disease.

AB - Neurocutaneous melanosis (NCM) is the condition of abnormal melanocyte deposition in the leptomeninges and brain parenchyma. Associated with congenital melanocytic nevi, NCM can result in neurologic deficits, hydrocephalus, and rarely, malignant transformation of cells. We present the case of a 16-year-old boy with NCM who developed malignant leptomeningeal melanoma following immunosuppression with a TNFα inhibitor. To our knowledge, this is the first reported case of a patient with known NCM undergoing malignant transformation after anti-TNF therapy for inflammatory bowel disease.

KW - TNF inhibitor

KW - immunodeficiency

KW - melanocytic nevi

KW - neoplasms-malignant

UR - https://www.scopus.com/pages/publications/85062989195

U2 - 10.1111/pde.13804

DO - 10.1111/pde.13804

M3 - Article

C2 - 30868657

SN - 0736-8046

VL - 36

SP - 497

EP - 500

JO - Pediatric Dermatology

JF - Pediatric Dermatology

IS - 4

ER -

Malignant transformation of neurocutaneous melanosis (NCM) following immunosuppression

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this